In the LEAD-6 trial, researchers followed nearly 500 patients with type 2 diabetes for a 26-week period. Participants were randomly assigned to one of two treatment groups: one group received Victoza (liraglutide) 1.8 mg once daily, while the other group was treated with Byetta (exenatide) 10 mcg twice daily. The trial aimed to compare the effectiveness and patient outcomes of these two GLP-1 receptor agonists.
The results showed that Victoza demonstrated superior efficacy compared to Byetta, with patients on Victoza experiencing a greater reduction in A1c levels (-1.1% vs. -0.8%), a key indicator of blood glucose control. This significant improvement in glycemic control suggests that Victoza may be more effective in helping patients achieve their target A1c goals.
Moreover, the convenience of once-daily dosing with Victoza, compared to the twice-daily requirement for Byetta, likely contributed to better patient adherence and overall treatment satisfaction. Victoza also demonstrated improved tolerability, with fewer gastrointestinal side effects, which are common with GLP-1 receptor agonists.
In conclusion, the LEAD-6 trial not only highlighted Victoza’s superior glucose-lowering effect but also emphasized the importance of convenience and tolerability in selecting optimal therapies for patients with type 2 diabetes. The combination of better efficacy, dosing convenience, and fewer side effects makes Victoza a more favorable option for many individuals managing diabetes.
